Gene therapy Archives

News and Trends 20 Dec 2016

UPDATE: UniQure keeps afloat with a New CEO and More Clinical Data

UniQure’s gene therapy for Hemophilia B is performing well in clinical trials, but the company faces many challenges with its current financial situation. Can it manage to make it to the market? UniQure is famous for launching Glybera, the first globally approved gene therapy, which has been a commercial failure. The company is now indefinitely missing […]

December 20, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

Screenshot 2016 12 16 at 10.22.38 AM e1481880436689

News and Trends 16 Dec 2016

This Gene Therapy Startup is Showing Off with a Better Viral Vector

GeneQuine wants to be one of the first to use gene therapy to treat osteoarthritis! Watch Kilian Guse’s pitch at Labiotech Refresh to find out how his startup plans to do this. “Osteoarthritis is the most common joint disorder. (…) Currently, there are only symptomatic treatments but no disease-modifying treatment“. One of the major challenges is efficient drug […]

December 16, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 12 Dec 2016

With a new €120M Infusion, Pocket NGS CEO talks Success and Strategy

Seeking to disrupt the NGS market, Oxford Nanopore is rolling in cash. Before we heard the news, we sat down with CEO Gordon Sanghera to talk about the company’s success. December has been a stellar month for Oxford Nanopore. Just over a week ago, Oxford Nanopore’s MinION device was used to sequence the whole genome of a number […]

December 12, 2016 - 9 minutesmins - By Evelyn Warner

News and Trends 29 Nov 2016

New British Partnership set to Cure Rare Diseases with Gene Therapy

Oxford BioMedica and Orchard Therapeutics are partnering up to bring gene therapy to the market and treat rare diseases for which no cure is available yet. Oxford BioMedica develops lentiviral vectors for gene and cell therapy applications. The company just announced a partnership with another biotech from the UK’s golden triangle, Orchard Therapeutics. The deal is […]

November 29, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 17 Nov 2016

UniQure takes an axe to its Pipeline and Workforce in new R&D Strategy

UniQure just announced a new R&D plan designed to save up to €27M over the next two years. Will the new strategy be enough to pull it out of its down spiral? UniQure is a Dutch biotech famous for launching Glybera, the first commercial gene therapy worldwide. However, the huge price of the treatment has […]

November 17, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 16 Nov 2016

Meet the CEO making the Next Generation of Gene Therapies Possible

How do you solve a problem like lentiviral vector infections? CEVEC has done it. We sat down with the CEO, Frank Ubags, to talk about his company’s success. The last few decades have not been kind to gene therapy companies, but the field seems to be on the edge of a renaissance with adenoviral vectors […]

November 16, 2016 - 6 minutesmins - By External Contributor

News and Trends 16 Nov 2016

Cell Therapies: Is Commercialization holding back a Breakthrough?

How far away is biotech from a breakthrough with cell and gene therapy? While these therapies have the potential to be the most effective on the market, they are still a long way away from that point, according to a pair of expert panels at BIO Europe last week. Everyone in cell therapy knows the […]

November 16, 2016 - 4 minutesmins - By Evelyn Warner

News and Trends 14 Nov 2016

USB key Diagnostic could help manage HIV Treatment Anywhere

A new method of gene sequencing has brought us an HIV diagnostic on a “USB stick”, which determines the levels of the virus with one drop of blood and in under 30 minutes. Once perfected, the technology could be the tool for HIV management as glucose meters are for diabetes. While pharma and research work […]

November 14, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 3 Nov 2016

CEVEC is Revolutionizing Industrial Protein & Viral Vector Production

CEVEC just filed a Biologics Master File (BB-MF) to the FDA for its CAP technology, which outperforms all current standards in the production of gene therapy vectors and glycosylated human proteins. CEVEC is a Biotech with the mission of raising the industrial standard for the large-scale production of glycosylated proteins, viral vaccines and gene therapy […]

November 3, 2016 - 2 minutesmins - By External Contributor

News and Trends 10 Oct 2016

The CRISPR Revolution is here, but how can we make it Useful?

By this point, you can’t have escaped hearing about CRISPR. First discovered in the 1980’s, the repeated sequences and their function in bacterial defense systems remained a mystery until almost 10 years ago, when it was hailed as the biggest scientific discovery of the century. Since then, scientists have leveraged the adaptable, heritable mechanism to develop the most powerful gene-editing technology […]

October 10, 2016 - 6 minutesmins - By External Contributor

News and Trends 1 Oct 2016

This Belgian Bioartist is deconstructing Chicken Evolution

Koen Vanmechelen is an artist that works in the intersection of art and research. His art focuses on exploring biocultural diversity… using chickens! Koen Vanmechelen‘s core artistic work is the Cosmopolitan Chicken Project (CCP), in which the artist cross-breeds chickens from all around the world. The aim: to create the ultimate chicken that will combine genes from […]

October 1, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 21 Sep 2016

A new player has entered the Game: €29M for DDR Cancer Therapy

Artios Pharma, launched in May this year, just received €29M (£25M) in Series A to develop cancer treatments. Its technology targets the DNA-Damage Response (DDR) and could overcome one of the main challenges of cancer therapy. Top-notch investors from Europe and the US have eagerly thrown cash at Artios Pharma in their search for new cancer treatments. […]

September 21, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us